Navigation Links
STEMCELL Technologies Applauds Feeder-free Derivation of Human Induced Pluripotent Stem Cells
Date:9/15/2009

R™1 is a fully defined medium and is the most widely used feeder-independent method for culturing human pluripotent stem cells, with citations in more than 25 publications.

About STEMCELL Technologies
STEMCELL Technologies Inc is a leader in the development and marketing of specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science and enabled by close interactions with global leaders in cell biology and medicine, STEMCELL delivers over 900 products to research scientists in more than 70 countries worldwide. To learn more about how STEMCELL helps to make research work, visit www.stemcell.com

Contact
STEMCELL Technologies Inc.
Clive Glover, PhD, Senior Product Manager
604 675 7723    

# # #

Read the full story at http://www.prweb.com/releases/2009/09/prweb2880454.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Neuralstem Responds to Incorrect StemCells, Inc. Release on Patents
2. STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
3. STEMCELL Technologies Launches Direct Distribution to Singapore
4. STEMCELL Technologies Inc. to Host Stem Cell Training Courses
5. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
6. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
7. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
8. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
9. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
10. Advanced technologies aim to transform the coaching of top athletes
11. Global Med Technologies(R) Extends Its Worldwide Outreach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... A Union County charitable ... Core Compassion Project is a non-profit organization dedicated to offering Pilates scholarships to ... cancer treatments and recover their mobility, strength, and range of motion following breast ...
(Date:9/4/2015)... Maui HI (PRWEB) , ... September 04, 2015 , ... ... the best ways for couples to explore, revitalize and strengthen their ‘couple-ness,’” says ... and his team at Four Seasons Resort Maui, the island’s only Forbes Five Star ...
(Date:9/4/2015)... , ... September 04, 2015 , ... The USC Eye ... ranked number 9 nationwide by Doximity. Faculty, residents and staff are honored to ... pride in the quality of our ophthalmology residency program. Our faculty places a high ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a ... followed up with victory in the men’s 400 meters final, with an impressive 44.89 ... Field Championships in San Jose, Costa Rica in August 2015. The 44.64 time is ...
(Date:9/4/2015)... ... September 04, 2015 , ... FiltersFast.com, the ... offer that cannot be passed up. FiltersFast.com, will ship all orders over ... water filtration product replacements. Take advantage of this promotion now through September 8, ...
Breaking Medicine News(10 mins):Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2
... patients who are infected with Clostridium difficile -- ... will lengthen their stay by about six days on average, ... to controlling the spread of the bacterial infection known as ... 5 in the journal CMAJ , researchers analyzed information ...
... M.D., M.S., assistant professor of medicine at the Indiana ... winner of the mHealth Alliance and Rockefeller Foundation,s Top ... goal is to recognize individuals who have used mobile ... outcomes particularly in the most remote areas of the ...
... , MONDAY, Dec. 5 (HealthDay News) -- Teenagers ... photosensitivity, or light sensitivity, researchers say. The combination ... such as flapping their hands in front of their ... Although photosensitivity occurs in up to 14 percent ...
... -- Children who suffer head trauma can experience headaches months after ... a new study finds. The researchers also found that the ... brain injury (TBI) than after a moderate or severe one. ... , included children aged 5 to 17 who were hospitalized ...
... By Alan Mozes HealthDay Reporter , SUNDAY, ... appear to face an increased risk for seizures while watching ... results did reveal that about one in five of these ... television, including nausea, headaches and dizziness. "Normal people have ...
... obese volunteers participating in a 12-week dietary weight-loss ... higher resting nerve activity compared to weight-loss resistant ... The Endocrine Society,s Journal of Clinical Endocrinology ... system is widely distributed throughout the body and ...
Cached Medicine News:Health News:Common Hospital Infection Lengthens Patient Stays 2Health News:Regenstrief investigator a winner of Top 11 in 2011 Innovator Challenge 2Health News:Girls More Prone Than Boys to Headaches After Head Injury 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 3Health News:Nervous system activity may predict successful weight loss 2
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
These grasping forceps are for fixation of the Fallopian tubes and feature a U-spring handle....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: